Atomoxetine, a selective norepinephrine (NE) reuptake inhibitor, was approved for attention
deficit/hyperactivity disorder (ADHD) treatment in children, adolescents and adults. We …

Objective: Systematic review and meta-analysis to estimate the pooled prevalence of ADHD
in adult attendees of outpatient mental health clinics and to investigate factors influencing …

Background Attention-deficit/hyperactivity disorder (ADHD) in adulthood, with an estimated
prevalence of 2–3%, is associated with several challenges in daily life functioning. Still, the …

The prevalence of attention deficit hyperactivity disorder (ADHD) in patients with epilepsy
was much higher than prevalence in general population, and vice versa. The mechanisms …

Attention deficit hyperactivity disorder (ADHD) is a common neurodevelopmental condition
worldwide. In this research, we used an ADHD electroencephalography (EEG) dataset …

Gene expression covaries with brain activity as measured by resting state functional
magnetic resonance imaging (MRI). However, it is unclear how genomic differences driven …

Attention-deficit hyperactivity disorder (ADHD) is a highly heritable neurodevelopmental
disorder that affects approximately 5.3% of children and approximately 2.5% of adults. There …

ADHD is a highly prevalent neurodevelopmental disorder. The first-line therapeutic for
ADHD, methylphenidate, can cause serious side effects including weight loss, insomnia …

Attention deficit hyperactivity disorder (ADHD) is a common childhood disorder, with only 2–
3% prevalence into adulthood. The epidemiology and proposed causes of ADHD are …

Attention deficit hyperactivity disorder (ADHD) is one of the most common
neurodevelopmental disorders, although the aetiology of ADHD is not yet understood. One …